AU2017353443B2 - Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines - Google Patents

Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines Download PDF

Info

Publication number
AU2017353443B2
AU2017353443B2 AU2017353443A AU2017353443A AU2017353443B2 AU 2017353443 B2 AU2017353443 B2 AU 2017353443B2 AU 2017353443 A AU2017353443 A AU 2017353443A AU 2017353443 A AU2017353443 A AU 2017353443A AU 2017353443 B2 AU2017353443 B2 AU 2017353443B2
Authority
AU
Australia
Prior art keywords
arenavirus
cancer
tumor
arenavirus particle
segment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017353443A
Other languages
English (en)
Other versions
AU2017353443A1 (en
Inventor
Lukas Roland FLATZ
Klaus Orlinger
Sandra Stephanie RING
Sarah Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neotrail Therapeutics Inc
Original Assignee
Neotrail Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotrail Therapeutics Inc filed Critical Neotrail Therapeutics Inc
Publication of AU2017353443A1 publication Critical patent/AU2017353443A1/en
Application granted granted Critical
Publication of AU2017353443B2 publication Critical patent/AU2017353443B2/en
Assigned to NeoTrail Therapeutics, Inc. reassignment NeoTrail Therapeutics, Inc. Request for Assignment Assignors: HOOKIPA BIOTECH GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017353443A 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines Active AU2017353443B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662417865P 2016-11-04 2016-11-04
US201662417891P 2016-11-04 2016-11-04
US62/417,891 2016-11-04
US62/417,865 2016-11-04
PCT/EP2017/078149 WO2018083220A2 (en) 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Publications (2)

Publication Number Publication Date
AU2017353443A1 AU2017353443A1 (en) 2019-05-02
AU2017353443B2 true AU2017353443B2 (en) 2024-11-14

Family

ID=60452580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017353443A Active AU2017353443B2 (en) 2016-11-04 2017-11-03 Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Country Status (7)

Country Link
US (2) US20200206334A1 (enExample)
EP (1) EP3534943A2 (enExample)
JP (2) JP2019533690A (enExample)
CN (1) CN110167586B (enExample)
AU (1) AU2017353443B2 (enExample)
CA (1) CA3039356A1 (enExample)
WO (1) WO2018083220A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
MX2023011054A (es) 2021-03-23 2023-11-22 Hookipa Biotech Gmbh Arenavirus utilizados en tratamientos del cáncer de próstata.
US20250073324A1 (en) * 2021-11-08 2025-03-06 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) * 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗

Also Published As

Publication number Publication date
WO2018083220A3 (en) 2018-12-13
JP2019533690A (ja) 2019-11-21
JP2023029898A (ja) 2023-03-07
CA3039356A1 (en) 2018-05-11
EP3534943A2 (en) 2019-09-11
CN110167586B (zh) 2024-01-30
WO2018083220A2 (en) 2018-05-11
CN110167586A (zh) 2019-08-23
US20200206334A1 (en) 2020-07-02
US20250009860A1 (en) 2025-01-09
AU2017353443A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US20250009860A1 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
US20220257734A1 (en) Arenavirus particles as cancer vaccines
US20200113995A1 (en) Arenavirus particles to treat solid tumors
CN107921117B (zh) Hpv疫苗
US20250073324A1 (en) Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
HK40070799A (en) Arenavirus particles as cancer vaccines
US20250057931A1 (en) Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
WO2025191169A1 (en) Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
HK1260579B (en) Arenavirus particles as cancer vaccines
HK1260579A1 (en) Arenavirus particles as cancer vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEOTRAIL THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): HOOKIPA BIOTECH GMBH